C4 Therapeutics to Participate in Upcoming November Investor Conferences

C4 Therapeutics (Nasdaq: CCCC) announced that management will participate in two investor conferences in November 2026, in Boston and London.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced that management will participate in two investor conferences in November 2026, in Boston and London.

A Guggenheim fireside chat is scheduled for November 9 at 11:00 am ET. A Jefferies presentation and fireside chat will take place on November 17 at 9:30 am GMT/4:30 am ET. Webcasts will be available on the company’s investor website, with replays available for approximately 90 days following the events.

Key Terms

targeted protein degradation

1 terms

targeted protein degradation technical

"dedicated to advancing targeted protein degradation (TPD) science"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 07:00 AM EST

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in upcoming investor conferences in November.

Guggenheim 3^rd Annual Healthcare Innovation Conference

Management will participate in a fireside chat on November 9, 2026, at 11:00 am ET, taking place in Boston, MA

2026 Jefferies Global Healthcare Conference in London

Management will participate in a presentation and fireside chat on November 17, 2026, at 9:30 am GMT/4:30 am ET, taking place in London UK.

The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. Archived replays of the webcasts will be available for approximately 90 days following the events.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com